One of the many concerns about President Obama’s health care legislation is that it will encourage—if not eventually require—the government to approve the cheapest rather than the best ...

In 2004, the FDA approved Avastin for the systemic treatment of metastatic colon cancer. Genentech later developed Lucentis, derived from a protein similar to Avastin, specifically for injection ...

That's when the National Institutes of Health will release the initial results of a National Eye Institute head-to-head study of the drugs Lucentis and Avastin as treatments for an eye condition ...

While Avastin is designed to treat cancer, not blindness, many doctors say it works just as well as Lucentis — with significant potential cost savings to patients, insurers, and the government.

Full publication of results from the head-to-head study of Avastin (bevacizumab) and Lucentis (ranibizumab) in "wet" age-related macular degeneration (AMD) confirmed information previously leaked ...

The valuation of Genentech shares is "less attractive," said SG Cowen, as blockbuster cancer drug Avastin could limit the potential of the biotech firm's promising blindness treatment, Lucentis.

Researchers say switching patients from Lucentis to Avastin eye diseases could save the government $18 billion. Deborah Weinstein June 3, 2014 5:30 pm Study: Using Avastin over Lucentis could save ...

Avastin and Lucentis: two drugs with roughly the same molecular structure, both manufactured by the same drugmaker. One is approved to treat cancer, the other wet age-related macular degeneration.

More fuel for the Avastin-vs-Lucentis debate: A big U.S. government study of the two drugs deemed them more or less equivalent for treating age-related macular degeneration. It's a finding that ...

The Lucentis/Avastin story is going to get more complicated as the year goes on. Next month the results of a head-to-head study of the two drugs (one far less costly than the other) in cases of ...

But a Lucentis treatment can cost $2,000, versus $50 for Avastin. So large potential savings are at stake for Medicare, the federal health insurance program that covers 54 million Americans age 65 ...

A new study, led by Dr. Daniel Martin, an ophthalmologist at the Cleveland Clinic’s Cole Eye Institute, has found that the cancer drug Avastin delivers the same benefits of the drug Lucentis ...